Brain fog on GLP-1 medicines

What the labels list close to brain fog

Labels list reactions using standard medical terms. Brain fog is a lay description that can cover tiredness, sleepiness, low mood, slower thinking and lightheadedness, so it does not map to a single row. We searched the US labels, the EU product information and the Canadian monographs for terms such as cognitive disorder, disturbance in attention and memory impairment and found none listed as a side effect. The entries below are the nearest.

When confusion is a warning sign

Two situations described in the product information make confusion more than a nuisance.

• Low blood sugar. GLP-1 medicines on their own rarely cause it, but the risk rises when they are taken with insulin or a sulfonylurea, and the labels ask prescribers to consider lowering those doses ^[2]. The Wegovy® medication guide and the EU Mounjaro® leaflet both list confusion among the signs ^[1][3].
• Diabetic ketoacidosis. The EU Ozempic® information warns that this has been reported in people who depend on insulin when their insulin was reduced quickly or stopped after starting a GLP-1 medicine. Its leaflet lists confusion with breathing difficulty, strong thirst and a sweet or fruity smell on the breath ^[5].

What research shows about thinking and memory

The largest trials of a GLP-1 medicine and cognition were evoke and evoke+, which gave oral semaglutide 14 mg or placebo to 3,808 people with early Alzheimer’s disease for up to three years. At two years, the dementia rating score had worsened by about the same amount in both groups. The authors also reported that safety matched what is known from other uses of semaglutide ^[6]. That result argues against a large effect on memory in either direction, although the trial population was older and already had Alzheimer’s disease.

A US Veterans Affairs cohort of people with diabetes found a lower risk of neurocognitive disorders, including dementia, among those who started a GLP-1 medicine than among those on usual care ^[7]. Observational studies like this cannot rule out differences between the people who received each treatment.

At the serious end, a 2026 systematic review found six published case reports of Wernicke’s encephalopathy, a brain disorder caused by lack of thiamine (vitamin B1), in people taking semaglutide for weight loss. Every patient had prolonged stomach symptoms and substantial weight loss before confusion and eye-movement problems began, and outcomes were poor in several, including lasting memory damage and death ^[8]. Separately, a single case report describes an older woman with dementia who became apathetic and lost weight on semaglutide and improved after it was stopped ^[9]. Case reports show what can happen, not how often.

How a GLP-1 medicine could contribute

• Supported by the labels: fatigue and dizziness are more common than on placebo, and the EU Wegovy® information notes that dizziness occurs mainly while the dose is being raised ^[1][2][4].
• Supported by the labels: vomiting and diarrhea can cause fluid loss ^[1][2], and fluid or electrolyte imbalance is a recognised cause of confusion ^[10].
• Proposed but not measured: eating much less may lower intake of nutrients such as thiamine and vitamin B12, both linked to confusion when deficient ^[10]. Whether this happens often on GLP-1 medicines has not been studied; the Wernicke cases involved prolonged vomiting ^[8].
• General: brain fog commonly follows poor sleep, stress and illness, all of which can overlap with the early weeks on a new medicine ^[10].

Other common causes

MedlinePlus lists many causes of confusion, from lack of sleep, fever and infections to low blood sugar, fluid or electrolyte imbalance, nutritional deficiencies, alcohol and other medicines ^[10]. Most of these are more likely explanations for a vague, foggy feeling than the GLP-1 medicine itself.

Obstructive sleep apnea deserves a special mention because it is common in people with obesity. Interrupted breathing at night leaves people drowsy during the day ^[11]. Zepbound® is approved to treat moderate to severe sleep apnea in adults with obesity ^[2], so for some people foggy mornings may be a reason to ask about a sleep assessment rather than a side effect.

What may help

There is no label advice for brain fog as such. The labels do give two practical points: learn the signs of low blood sugar if you also take insulin or a sulfonylurea, and take care to avoid fluid loss when stomach side effects are active ^[1][2]. The EU product information adds that driving or using machines calls for care if you feel dizzy, and that people on a sulfonylurea or insulin should guard against low blood sugar while driving ^[3][4][12].

MedlinePlus suggests that sudden confusion from low blood sugar caused by a diabetes medicine is treated with a sweet drink or snack, with a call to the clinician if it lasts longer than ten minutes ^[10]. Beyond that, the usual steps for a clearer head, such as regular sleep and enough fluids and food, are worth discussing with your care team, especially if your appetite has dropped sharply.

Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.

When to get help